Introduction
============

Renal cell carcinoma (RCC) is a malignancy thought to arise from epithelial cells of the renal tubules and accounts for \~85% kidney cancers ([@b1-or-34-02-0567]). The incidence of RCC has steadily shown a worldwide increase of 2--4% annually ([@b2-or-34-02-0567]). Clinical manifestations of RCC are diverse and may lead to a range of non-specific and often misattributed symptoms ([@b3-or-34-02-0567]). The classic triad of hematuria, flank pain and a flank mass has been suggested in only 10% of patients; however, \>60% of the RCC are detected incidentally in patients not suspected of harboring a genitourinary malignancy ([@b4-or-34-02-0567]). RCC has the highest mortality rate of the genitourinary cancers, as more than a third of patients with RCC are expected to succumb to the disease ([@b5-or-34-02-0567]). Thus, identification of effective therapies and etiologic explanations of RCC is crucial.

The development of large scale of gene expression analysis has led to therapies at the gene level becoming more powerful and informative for the study of disease mechanism ([@b6-or-34-02-0567]). For RCC, much has been accomplished since the identification of the Von Hippel-Lindau (*VHL*) in 1993 ([@b7-or-34-02-0567]). *p53*, a tumor suppressor gene, when mutated inactivates the normal function of DNA damage surveillance ([@b8-or-34-02-0567]). Additionally, some genes associated with RCC are typically detected through the analysis of many differentially expressed (DE) genes. The importance of these genes is evident in individual marker gene detection.

Despite the rich transcriptome data, identifying the disease mechanism involved remains a major challenge. Inconsistent results have been presented due to multiple issues of concern, including small sample size, measurement error and different statistical methods. The overlap is very low for the most significantly dysregulated genes across multiple studies ([@b9-or-34-02-0567]). Based on the deficiency, a more effective means has been adopted by combining gene expression measurements over groups of genes that can be classified within common pathways. It identifies cancer markers by scoring known pathways by evaluating the coherency of genes expression changes ([@b10-or-34-02-0567]). However, a large number of human genes have not yet been assigned to a definitive pathway based on pathway analysis. Network-based approaches particularly co-expression network offer an effective means to at least partially solve this challenge by providing potential malignancy diagnostic molecular and connecting them together. However, the results of the co-expression network are different when applying various constructed approaches, and there is a lack of methods to assess any reliable and comprehensive experimental data available.

In the present study, we created a novel method to integrate the gene-gene interaction correlations identified by a multiple co-expression network strategy, following a network-based pathway enrichment analysis. To achieve this, we first identified DE genes between RCC patients and normal controls using a linear Models for Microarray Data package, since we only focused on the shifted genes. The backbone of the co-expression networks was constructed using the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) database. Differentially co-expressed links were obtained based on the Pearson's correlation score, empirical Bayesian (EB) approach and Weighted Gene Co-expression Network Analysis (WGCNA) based on DE genes of RCC. We ranked the gene pairs by the strength of their correlation for each method, and merged gene pairs by a rank-based algorithm. Furthermore, the pathway enrichment analysis based on the Kyoto Encyclopedia of Genes and Genomes (KEGG) database and the network enrichment analysis (NEA) method were performed to show the feasibility of the novel method.

Materials and methods
=====================

Identification of gene expression datasets and dataset preprocessing
--------------------------------------------------------------------

Microarray expression profiles of RCC from Array Express with access no. E-GEOD-26574 ([@b11-or-34-02-0567]), E-GEOD-36895 ([@b12-or-34-02-0567]), E-GEOD-46699 ([@b13-or-34-02-0567]) and E-GEOD-53757 ([@b14-or-34-02-0567]), were selected to identify DE genes between RCC patients and normal controls. The four datasets were obtained from the Affymetrix GeneChip Human Genome U133 Plus 2.0 Array platform.

For each dataset, we applied standard methods to control the quality of gene microarray probe-level data ([@b15-or-34-02-0567]). Briefly, to eliminate the effect of non-specific hybridization, background correction and quantile normalization were applied by the RMA method ([@b16-or-34-02-0567]) and quantile-based algorithm ([@b17-or-34-02-0567]). The quantile normalization method was a specific case of the transformation *x*′*~i~*=F^−1^(G (*x~i~*)), where *G* was estimated by the empirical distribution of each array and *F* using the empirical distribution of the averaged sample quantiles. The perfect match (PM) and mismatch (MM) values were revised using MAS algorithm ([@b15-or-34-02-0567]), where the ideal MM would always be less than the corresponding PM and thus could be safely subtracted without risk of obtaining negative values. The summarization method was median polish ([@b16-or-34-02-0567]). A multichip linear model was fit to the data from each probe set. In particular for the probe set *k* with *i*=1, ..., *I~k~* probes and data from *j*=1,..., *J* arrays were fitted according to the model: where *α~i~* was a probe effect and *β~j~* was the log~2~ expression value.

The data were subsequently screened by the feature filter method of the gene filter package, and the amount of genes with multiple probes was 20,109. The gene expression value for each gene was obtained, including 20,109 genes from 417 samples (179 normal controls and 238 RCC patients).

Merging the multiple datasets
-----------------------------

To calculate the co-expression value, it was necessary to merge all the independent data into a single dataset. Thus, the GenNorm method was applied to remove the unwanted batch effects in the gene expression values resulting from the use of different experimentation plans and methodologies in order to actually merge different datasets, as introduced by Taminau *et al* ([@b18-or-34-02-0567]). The GenNorm method in an intuitive manner, which made datasets more comparable at z-score normalization and the expression values were calculated ([@b19-or-34-02-0567]). The modified gene expression value $Y_{ij}^{k}$ was given by the expression: where *X~ij~* indicated each gene expression value in each study, ${\overline{X}}_{i}^{k}$ indicated mean gene expression value in the dataset, *K* indicated the number of studies and $\sigma_{i}^{k}$ indicated the standard deviation of the gene expression value.

The distribution of the combined data was inspected using a qualitative validation method to observe visually whether the samples from all the studies would cluster together or have a dataset-bias ([@b20-or-34-02-0567]).

Detection of DE genes
---------------------

The linear Models for Microarray Data method was used to detect DE genes between RCC patients and normal controls based on 20,109 filtered genes. The P-values for all the genes were converted into the form of -log10 after being manipulated with t- and F-tests. Linear fit, empirical Bayes statistics and false discovery rate (fDR) correction were performed to the data by using Fit function ([@b21-or-34-02-0567]). De genes were identified for further research with the threshold of P\<0.05 and \|log~2~FC\| \>2.

Identification of gene-gene interaction correlations by multiple methods
------------------------------------------------------------------------

Co-expression networks are instrumental for describing the pairwise relationships among the gene transcripts. Specifically, functionally related genes are frequently co-expressed across the samples. The co-expression network derived from the database and multiple co-expression approaches were considered a framework. The backbone of the network based on DE genes was constructed using the STRING database. Differentially co-expressed links were then detected by Pearson's correlation, the EB approach and WGCNA.

Construction of the backbone of the co-expression network using the STRING database
-----------------------------------------------------------------------------------

In this section, we investigated possible functional associations of DE gene pairs using the STRING database which provided a comprehensive, albeit quality-controlled collection of gene/protein associations for a large number of organisms with a global perspective ([@b22-or-34-02-0567]). It is a carefully curated database that combines several different types of data. It comprises i) gene neighborhood and fusion, and phylogenetic profiles of the genomic context; ii) the co-occurrence and the co-expression of genes (i.e., variation of the transcript levels under the same conditions) by means of literature curation; iii) experimental evidence extracted from experimentally derived protein-protein interactions; iv) manually curated pathway databases; and v) text mining and homology in order to identify the co-mentioned genes ([@b22-or-34-02-0567]). STRING assessed and integrated these data to obtain a confidence score for all protein/gene interactions. A sub-network was created using De genes, which was identified as mentioned in 'Detection of DE genes'.

After assignment of the association scores, a final 'combined score' was computed between any pair of proteins. The combined scores were defined as the strength of the correlation and computed under the assumption of independence for the various sources, in a naive Bayesian manner. It was thus a simple expression of the individual scores ([@b23-or-34-02-0567]):

Evidence of the co-expression (individual scores) was chosen to describe the gene pairs with co-expression and the scores attributed by the STRING database between 0 and 1 to indicate the strength of the prediction were given.

Construction of teh co-expression network using Pearson's correlation test
--------------------------------------------------------------------------

In this study, we identified differentially co-expressed (DC) genes based on DE genes between RCC patients and normal controls using Pearson's correlation test ([@b24-or-34-02-0567]). PPIs weighted by the absolute average of Pearson's correlation coefficients (PCCs) of the interacting gene pairs in the compared samples $\left( \left| {\overline{r}}_{E_{ij}} \right| \right),\left| {\overline{r}}_{E_{ij}} \right|$ and $\left| {\Delta r_{E_{ij}}} \right|$ were calculated: where *E~ij~* was the interactions between gene pairs *V~i~* and *V~j~*, *k* was the *kth* sample, *V~i~* and *V~j~* were ranked by their expression in the samples, respectively, and *X~jk~* was the rank of *V~i~* of the *kth* sample, *X~ik~* was the rank of *V~j~* of the *kth* sample, ${\overline{x}}_{i}$ and ${\overline{x}}_{j}$ were the average ranks of *V~i~* and *V~j~* in the samples, respectively. where *r~Eij~*~1~ and *r~Eij~*~2~ were the PCCs of *E~ij~* in the compared samples, respectively. Non-informative correlation pairs were filtered out with the half-thresholding strategy and a pair was kept in case the two PCCs had a q-value, where the q-value was an FDR estimated from the P\<0.05 of PCC ([@b25-or-34-02-0567]). We then defined $\left| {\Delta\mathbf{r}_{E_{ij}}} \right|$ as the strength of the correlation in this method.

Construction of co-expression network by the EB approach
--------------------------------------------------------

A number of methods have been developed for co-expression analysis to identify DC gene pairs. However, these methods yield false findings under the conditions of large cardinality of the space to be interrogated ([@b26-or-34-02-0567]). In this study, an effective approach of EB framework was conducted that provided an fDR controlled list of interesting pairs along with pair-specific posterior probabilities ([@b27-or-34-02-0567]). The identification of DC gene pairs was processed at the following steps: three inputs of matrix X, the conditions array and the pattern object required. The expression values in an *m*-by-*n* matrix of X (where m indicated the number of genes/probes under consideration and n the total number of microarrays over all conditions) were normalized with background normalization and median correction and were generally represented on the log~2~ scale. The members of the conditions array with length *n* took values in 1,......, *K* (*K* indicated the total number of conditions). It was used to define the EC/DC classes with an 'ebarraysPatterns' object based on the unique values in the conditions array. Intra-group correlations for all *p=m\**(*m*-1)/2 gene pairs from X and the conditions array were calculated using bi-weight mid-correlation through the function makeMyD. The *p*-by-*K* of D matrix with correlations was obtained. The Mclust algorithm ([@b28-or-34-02-0567]) was used to initialize the hyper parameters through the initializeHP function to detect the component in the normal mixture model that best fit the empirical distribution of correlations. The values of the component in the normal mixture model with component means, standard deviations and weights was used to initialize the expectation maximization (eM) algorithm ([@b29-or-34-02-0567]). The three functions of the 'full', the 'one-step' and the 'zero-step' versions were different factors of the modified eM approach. In this step, the initial estimates of the hyper parameters rather than the 'zero-step' version were used to generate posterior probabilities of DC. After the eM computations were finished with the selected function, the prior diagnostic function for the prior predictive distribution was used to determine how well the model identified by the eM fit the data. The crit.fun function was used to provide a soft threshold by controlling the posterior probabilities of DC in order to identify particular types of DC gene pairs. The DC genes were distinguished from gene pairs having an invariant expression by controlling the posterior expected FDR at 0.05 and the co-expression network was constructed to represent the correlation between each pair of genes. In addition, we defined the DC as the strength of the correlation in this method.

Construction of the co-expression network by WGCNA
--------------------------------------------------

WGCNA was frequently used to describe correlation patterns among gene expression profiles ([@b30-or-34-02-0567]). For this method, the first step was to define a measure of similarity between the gene expression profiles. The *n*x*n* similarity matrix *S* = \[*s~ij~*\] was transformed into an *n*x*n* adjacency matrix A = \[*a~ij~*\] which encoded the connection strength between pairs of nodes. For each pair of genes *x~i~* and *x~j~* indicated similarity measured by *S~ij~*. we defined the absolute value of the Pearson's correlations *S~ij~* = \|*cor*(*x~i~*, *x~j~*)\| of an unsigned network by employing a value between 0 and 1. However, a signed co-expression measure between *x~i~* and *x~j~* was applied to preserve the sign of the correlation which was defined with a simple transformation of the correlation:

The adjacency function was used to determine the adjacency matrix A = \[*a~ij~*\]. The most widely used adjacency function was the signum function that implements a 'hard' threshold involving the threshold parameter τ:

The hard threshold may lead to a loss of information; therefore a 'soft' adjacency function was needed. The power adjacency function was calculated as: *a~ij~* = \|*s~ij~*\|^β^ with the single parameter *β*.

As for the overlap of two nodes, which reflects their relative interconnectedness, the topological overlap matrix (ToM) Ω = \[*ω~ij~*\] provided a similarity measure. To turn it into a dissimilarity measure, it was subtracted from one, i.e, the topological overlap based dissimilarity measure was defined by $d_{ij}^{\omega} = 1 - \omega_{ij}.$ In addition, we defined the weight value as the strength of the correlation in this method.

Merging of co-expressed gene pairs
----------------------------------

Determination of the significance of the changes occurring and the number of selected gene pairs likely to be truly differentially co-expressed is important. After gene co-expression was analyzed using the above four methods, the score of each co-expressed gene pair was obtained. Considering the results were different due to utilizing various approaches, all the score values were assessed further to ensure their uniformity and converted in the form of rank/(total number of gene pairs) based on the Rank Products (RP) algorithm ([@b31-or-34-02-0567]).

The RP-values were calculated over all the possible pairwise comparisons. The algorithm *i* (*i* = STRING database, Pearson's correlation, EB approach and WGCNA), each examining *n* gene pairs were considered, whereby the RP for a certain gene pair *g* would be:

This was potentially interpreted as a P-value (=RP-value), as it described the probability of observing gene pair *g* at a certain rank (rank^algorithm^ *^i^*), with *λ~i~* being the weight coefficient of each algorithm. If the gene pairs were not differentially co-expressed in any method, the weight value of pairwise in this method would equal to 1.

Subsequently, for each gene pair *g*, a conservative estimate of the percentage of false-positives (PFP) was calculated when this gene pair (and all the gene pairs with RP-values smaller than this cut-off value) was considered as significantly differentially co-expressed: *q~g~* = *E*(RP*~g~*)/rank(*g*). In the present study, rank(*g*) denoted the position of gene pair *g* in a list of all the gene pairs sorted by the increasing RP-value, i.e., it was the number of gene pairs accepted as significantly regulated. This estimated the FDR and extended the list of accepted gene pairs up to the gene pair with a *q~g~*-value of \<0.1. The DC gene pairs were therefore obtained for subsequent study.

Pathway enrichment analysis
---------------------------

To verify the feasibility of the merged method, the pathway enrichment analysis of DC gene pairs based on the KEGG database and NEA method were performed in this study.

KEGG database
-------------

To investigate the biological functions of the DE genes, KEGG pathway enrichment analysis was performed by Database for Annotation, Visualization and Discovery (DAVID) ([@b32-or-34-02-0567]). KEGG pathways with P\<0.01 were chosen based on the Expression Analysis Systematic Explorer (EASE) test applied in DAVID. EASE analysis of the regulated genes indicated molecular functions and biological processes unique to each category ([@b33-or-34-02-0567]). The EASE score was used to detect the significant categories. The threshold of eASe score \<0.01 and the minimum number of genes for the corresponding term \>2 were considered significant for a category. where *n* (*n* = *a*′*+b+c+d*) was the number of background genes, *a*′ was the gene number of one gene set in the gene lists, *a*′ + *b* was the number of genes in the gene list including at least one gene set, *a*′ + *c* was the gene number of one gene list in the background genes and *a'* was replaced with *a* = *a*′-1.

Network enrichment analysis method
----------------------------------

A NEA method, which systematically implemented the network approach to describe novel gene sets with biologically meaningful functional categories, was selected to analyze DC gene pairs of RCC ([@b34-or-34-02-0567]). A fast network randomization algorithm was used in the method to obtain the distribution of any network statistics under the null hypothesis of no association between an altered gene sets (AGS) and functional gene sets (FGS) ([@b35-or-34-02-0567]).

To investigate the functional heterogeneity of individual RCC, we ranked the differences between individuals. The differential expression of gene *g* in patient *i* compared to the group of patients was calculated as: Difference values = log(*T/N*) *ig* − ave(log(*T/N*)).*~g~*, where log(T/N) was the log intensity-ratio of RCC vs. normal expression. Let *A*(*k*) was an AGS of size *k*, and define *n~AF~*(*k*), a measure of network connectivity between *A*(*k*) and a known FGS (*F*), as the number of links between members of *A*(*k*) and *F*. Since the connectivity was dependent on the constituent genes, we corrected *n~AF~*(*k*) by its expected value: *d~AF~*(*k*) = *n~AF~*(*k*)−*μ~AF~*(*k*), where *μ~AF~*(*k*) was the expected number of links between A(*k*) and *F*.

Results
=======

Identification of the DE genes
------------------------------

In total, 20,109 genes in E-GEOD-26574, E-GEOD-36895, E-GEOD-46699 and e-GeoD-53757 were identified by reading the gene expression profiles using an Affy package. After preprocessing of the expression profile dataset, we obtained 753 De genes between RCC patients and normal controls with the thresholds of P\<0.05 and \|log~2~FC\| \>2.

Analysis of co-expression networks
----------------------------------

In the present study, the co-expression networks of 753 DE genes were constructed by four methods (STRING database, Pearson's correlation tests, EB approach and WGCNA). We achieved a co-expressed relationship between gene and gene or co-expressed gene pairs and scores of gene pairs.

We obtained 842 co-expressed gene pairs of RCC based on the STRING database. According to the Pearson's correlation tests, 371 co-expressed gene pairs were obtained. We achieved 2,883 co-expressed gene pairs dependent on the EB method with the threshold fDR ≤0.05. when constructing the co-expression network of DE genes using the WGCNA method, 1,595 co-expressed gene pairs were obtained. The number of co-expressed gene pairs based on the EB approach was higher than that of the other three methods. The genes at the top of degree distribution (≥90% quantile) in the significantly perturbed co-expression networks were defined as hub genes. The co-expression networks of hub genes from the four methods are shown in [Fig. 1](#f1-or-34-02-0567){ref-type="fig"}.

Merging of the co-expressed gene pairs
--------------------------------------

We merged all the co-expressed gene pairs identified from the four methods utilizing RP algorithm, and 13,945 genes were assessed after merging. Two hundred and eighty one DC gene pairs were obtained after q-value correction (P\<0.1) and their co-expression network is shown in [Fig. 2](#f2-or-34-02-0567){ref-type="fig"}. There were 154 nodes and 281 edges in the co-expression network.

Pathway enrichment analysis
---------------------------

For the KEGG pathway enrichment analysis, our results showed that 753 DE genes were significantly enriched in 130 terms. Co-expressed gene pairs obtained from the four methods and 281 DC gene pairs were enriched in pathways, with the cytokine-cytokine receptor interaction and systemic lupus erythematosus being common pathways of the five types of co-expressed gene pairs. Thirteen pathways were obtained from 281 DC gene pairs ([Table I](#tI-or-34-02-0567){ref-type="table"}). Counts of cytokine-cytokine receptor interaction, chemokine signaling pathway, cell adhesion molecules, toll-like receptor signaling pathway and the neuroactive ligand-receptor interaction were increased by 10.

The NEA method was performed on 281 DC genes using a neaGUI package in R ([Table II](#tII-or-34-02-0567){ref-type="table"}). The metabolic pathways had the highest number links with 1,282, the following was phagosome, chemokine signaling pathway, cell adhesion molecules and natural killer cell-mediated cytotoxicity.

Discussion
==========

In the present study, co-expression networks were constructed using the STRING database, Pearson's correlation tests, EB method and WGCNA method. We merged these co-expressed gene pairs together using RP algorithm and scored 281 DC gene pairs. The KEGG pathway enrichment analysis and NEA method were selected to verify the feasibility of this merged method. The results show that cytokine-cytokine receptor interaction and metabolic pathways were the most significant biological processes that were closely associated with RCC.

Diagnostic or prognostic markers were usually obtained by identification of the most significant DE genes in the high-throughput case-control studies of a disease. However, previous findings have shown that the most significant De genes obtained from different studies for a particular cancer are typically inconsistent ([@b36-or-34-02-0567]). To overcome this problem, significant genes and biological processes were assessed for disease-association using a network strategy, particularly the co-expression network ([@b37-or-34-02-0567]). When constructing a co-expression network, the STRING database is the most commonly used method. Of note is that a few other approaches have been developed for co-expression analysis, such as the Pearson's correlation tests, EB approach and WGCNA.

There are some drawbacks to employing these methods ([@b38-or-34-02-0567]). For the STRING database, the networks, which are supposed to be static, may not reflect the specific condition of the individuals or specific disease. For the Pearson's correlation tests, all possible variations are measured although are the effects on gene expression not considered, thereby producing many false-positive results. The EB approach examines network variations and their effects on gene expression. Nevertheless a disease-associated gene may lead to the differential expression of its interacting genes even if there is no network rewiring in certain situations. WGCNA suggested a tight network that was closer to properties of small networks in a general framework as compared to the Pearson's correlation tests.

Therefore, we developed a new method by merging co-expressed gene pairs together to overcome these problems based on an RP algorithm. In our merged method, weight value was utilized to reflect the differential importance of each method, and the weight of each dataset was set equally since we treated all the datasets equally. If certain reliable properties serve as the backbone, a decrease in the weight value is merely required. For instance, in the given database, if it occupied the dominant position, we would select 0.1 as its weight value and 1 for the remaining methods. The merged method provides a straightforward and statistically stringent means to determine the significance level for each gene pair, allowing for the flexible control of the false-detection rate and familywise error rate in the multiple testing ([@b31-or-34-02-0567]).

Results of the merged method showed that the cytokine-cytokine receptor interaction and metabolic pathways were the most significant biological processes of RCC. Cytokines that were crucial intercellular regulators mobilized cells engaged in innate as well as adaptive inflammatory host defenses, cell growth and cell death ([@b39-or-34-02-0567]). Cytokine receptors functioned to inhibit tumor development and progression in response to infection, inflammation and immunity. A more detailed understanding of cytokine-tumor-cell interactions provided new opportunities for improving cancer immunotherapy, such as RCC ([@b40-or-34-02-0567]). It has been reported that the tumor response in treatment-naive and cytokine-pretreated patients is associated with advanced metastatic RCC ([@b41-or-34-02-0567]). Therefore, the cytokine-cytokine receptor interaction pathway was closely associated with RCC, suggesting that the merged method was feasible.

Linehan *et al* found that mutations in each of kidney cancer genes resulted in dysregulation of metabolic pathways, suggesting that kidney cancer is a disease of cell metabolism ([@b42-or-34-02-0567]). In addition, metabolic activities in proliferating cells are fundamentally different from those in non-proliferating cells, and are associated with signal transduction pathways and transcriptional networks of RCC ([@b43-or-34-02-0567]). The essential hallmarks of cancer were intertwined with an altered cancer cell-intrinsic metabolism. Additionally, the constitutive activation of signaling cascades that stimulate cell growth has a profound impact on the anabolic metabolism ([@b44-or-34-02-0567]). Thus cancers, for example RCC, were closely associated with cell metabolism.

In conclusion, we created a novel merged method to identify genes and pathways associated with RCC, and the KEGG and NEA pathway analyses have shown the correctness and feasibility of this method. The recommended method is computationally efficient to identify genes and pathways of RCC and has been proven to be a useful complement to traditional co-expression analysis.

This study received no specific grants from any funding agency in public, commercial or not-for-profit sectors.

![Co-expression networks based on hub genes of RCC from co-expression networks constructed by the (A) STRING database, (B) Pearson's correlation tests, (C) eB method and (D) wGCNA. Genes (nodes) are connected by edges if their vectors are sufficiently similar. Black edge is associated with a pair of genes under thresholds. RCC, renal cell carcinoma; STRING, Search Tool for the Retrieval of Interacting Genes/Proteins; EB, empirical Bayesian; WGCNA, Weighted Gene Co-expression Network Analysis.](OR-34-02-0567-g10){#f1-or-34-02-0567}

![Co-expression network of 281 DC gene pairs of RCC from the merged matrix. Genes (nodes) are connected by edges if their vectors are sufficiently similar. Black edge is associated with a pair of genes with q-value correction (P\<0.1). DC, differentially co-expressed; RCC, renal cell carcinoma.](OR-34-02-0567-g11){#f2-or-34-02-0567}

###### 

KEGG pathways based on 281 DC gene pairs.

  Term                                                           Counts
  -------------------------------------------------------------- --------
  Cytokine-cytokine receptor interaction                         24
  Chemokine signaling pathway                                    16
  Cell adhesion molecules (CAMs)                                 14
  Toll-like receptor signaling pathway                           13
  Neuroactive ligand-receptor interaction                        12
  Systemic lupus erythematosus                                   10
  Natural killer cell-mediated cytotoxicity                      9
  Oxidative phosphorylation                                      8
  Aldosterone-regulated sodium reabsorption                      8
  *Vibrio cholerae* infection                                    7
  Epithelial cell signaling in *Helicobacter pylori* infection   6
  Lysosome                                                       5
  Fc ε RI signaling pathway                                      3

KEGG, Kyoto Encyclopedia of Genes and Genomes; DC, differentially co-expressed.

###### 

Results of NEA based on 281 DC gene pairs.

  Path_name                                                      No. of links
  -------------------------------------------------------------- --------------
  Metabolic pathways                                             1,282
  Phagosome                                                      848
  Chemokine signaling pathway                                    800
  Cell adhesion molecules (CAMs)                                 701
  Natural killer cell-mediated cytotoxicity                      653
  Osteoclast differentiation                                     609
  Cytokine-cytokine receptor interaction                         603
  Leishmaniasis                                                  578
  Toxoplasmosis                                                  563
  Regulation of actin cytoskeleton                               554
  Fc γ R-mediated phagocytosis                                   529
  Leukocyte transendothelial migration                           529
  *Staphylococcus aureus* infection                              502
  Rheumatoid arthritis                                           501
  Neuroactive ligand-receptor interaction                        489
  Pathways in cancer                                             480
  Viral myocarditis                                              479
  Antigen processing and presentation                            438
  T-cell receptor signaling pathway                              438
  Systemic lupus erythematosus                                   411
  Hematopoietic cell lineage                                     406
  Fc ε RI signaling pathway                                      388
  B cell receptor signaling pathway                              382
  Endocytosis                                                    373
  Autoimmune thyroid disease                                     356
  Graft-vs.-host disease                                         354
  Type I diabetes mellitus                                       351
  Allograft rejection                                            347
  Intestinal immune network for IgA production                   344
  Focal adhesion                                                 327
  Jak-STAT signaling pathway                                     318
  Toll-like receptor signaling pathway                           311
  Chagas disease (American trypanosomiasis)                      289
  Calcium signaling pathway                                      263
  Asthma                                                         254
  Amoebiasis                                                     253
  Olfactory transduction                                         251
  Neurotrophin signaling pathway                                 251
  Lysosome                                                       248
  Cell cycle                                                     247
  Bacterial invasion of epithelial cells                         237
  VEGF signaling pathway                                         231
  Purine metabolism                                              225
  Primary immunodeficiency                                       222
  Hepatitis C                                                    221
  RNA transport                                                  219
  Pathogenic *Escherichia coli* infection                        216
  Oocyte meiosis                                                 204
  Epithelial cell signaling in *Helicobacter pylori* infection   203
  Drug metabolism-cytochrome P450                                194
  Shigellosis                                                    190
  Pyrimidine metabolism                                          188
  Spliceosome                                                    185
  Protein processing in endoplasmic reticulum                    184
  Axon guidance                                                  184
  Pancreatic cancer                                              180
  Metabolism of xenobiotics by cytochrome P450                   177
  Cytosolic DNA-sensing pathway                                  173
  Adherens junction                                              168
  Huntington's disease                                           160
  Retinol metabolism                                             158
  Drug metabolism - other enzymes                                157
  Apoptosis                                                      157
  Complement and coagulation cascades                            156
  Pancreatic secretion                                           156
  Colorectal cancer                                              155
  Wnt signaling pathway                                          154
  *Vibrio cholerae* infection                                    154
  Arachidonic acid metabolism                                    147
  Alzheimer's disease                                            146
  Malaria                                                        146
  Small cell lung cancer                                         144
  Long-term depression                                           143
  Oxidative phosphorylation                                      142
  Phosphatidylinositol signaling system                          141
  NOD-like receptor signaling pathway                            138
  Acute myeloid leukemia                                         133
  Non-small cell lung cancer                                     133
  DNA replication                                                130
  Salivary secretion                                             125
  Steroid hormone biosynthesis                                   118
  Starch and sucrose metabolism                                  118
  Dilated cardiomyopathy                                         117
  Ubiquitin-mediated proteolysis                                 114
  Amyotrophic lateral sclerosis (ALS)                            114
  mRNA surveillance pathway                                      110
  Melanogenesis                                                  109
  Hypertrophic cardiomyopathy (HCM)                              106
  Glycerophospholipid metabolism                                 105
  Type II diabetes mellitus                                      104
  Carbohydrate digestion and absorption                          103
  Porphyrin and chlorophyll metabolism                           102
  Glutathione metabolism                                         100
  Linoleic acid metabolism                                       97
  Ribosome biogenesis in eukaryotes                              97
  Other types of O-glycan biosynthesis                           96
  Adipocytokine signaling pathway                                96
  Aldosterone-regulated sodium reabsorption                      95
  Long-term potentiation                                         94
  p53 signaling pathway                                          93
  Pentose and glucuronate interconversions                       92
  RNA degradation                                                91
  Inositol phosphate metabolism                                  88
  Bile secretion                                                 88
  Ascorbate and aldarate metabolism                              86
  Prion diseases                                                 86
  eCM-receptor interaction                                       82
  Collecting duct acid secretion                                 82
  Arginine and proline metabolism                                79
  Proteasome                                                     78
  Parkinson's disease                                            78
  Nucleotide excision repair                                     75
  TGF-β signaling pathway                                        74
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